Data / Drug companies / Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc.: 21 products in the FDA NDC directory, labeler code 66215
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Actelion Pharmaceuticals US, Inc. (labeler code 66215) lists 21 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 21 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on May 23, 2026.
The request: Watch Actelion Pharmaceuticals US, Inc. (FDA labeler code 66215): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 66215
- Products in commercial distribution
- 21
- Packages
- 28
- Finished drugs by generic name
- 6
- Prescription products
- 21
- Over the counter products
- 0
- Flagged as original packager
- 21 of 21 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- November 20, 2001
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 21 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 21 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Selexipag | 12 | 3 |
| Bosentan | 3 | 7 |
| Macitentan and tadalafil | 2 | 1 |
| Epoprostenol | 2 | 4 |
| Macitentan | 1 | 15 |
| Miglustat | 1 | 7 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, coated | 8 | 38.1% |
| Tablet, film coated | 7 | 33.3% |
| Injection, powder, lyophilized, for solution | 2 | 9.5% |
| Tablet, for suspension | 1 | 4.8% |
| Injection, powder, for solution | 1 | 4.8% |
| Capsule | 1 | 4.8% |
| Kit | 1 | 4.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Prostacyclin Receptor Agonist | 11 |
| Endothelin Receptor Antagonist | 6 |
| Phosphodiesterase 5 Inhibitor | 2 |
| Prostacycline Vasodilator | 2 |
| Glucosylceramide Synthase Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Uptravi | 66215-915 | Tablet, film coated | New drug applications (NDA) | May 23, 2026 |
| Uptravi | 66215-910 | Tablet, film coated | New drug applications (NDA) | May 23, 2026 |
| Opsynvi | 66215-814 | Tablet, film coated | New drug applications (NDA) | March 22, 2024 |
| Opsynvi | 66215-812 | Tablet, film coated | New drug applications (NDA) | March 22, 2024 |
| Uptravi | 66215-718 | Injection, powder, for solution | New drug applications (NDA) | July 29, 2021 |
| Tracleer | 66215-232 | Tablet, for suspension | New drug applications (NDA) | July 29, 2021 |
| UPTRAVI Titration Pack | 66215-628 | Kit | New drug applications (NDA) | December 21, 2015 |
| Uptravi | 66215-616 | Tablet, coated | New drug applications (NDA) | December 21, 2015 |
| Uptravi | 66215-614 | Tablet, coated | New drug applications (NDA) | December 21, 2015 |
| Uptravi | 66215-612 | Tablet, coated | New drug applications (NDA) | December 21, 2015 |
| Uptravi | 66215-610 | Tablet, coated | New drug applications (NDA) | December 21, 2015 |
| Uptravi | 66215-608 | Tablet, coated | New drug applications (NDA) | December 21, 2015 |
| Uptravi | 66215-606 | Tablet, coated | New drug applications (NDA) | December 21, 2015 |
| Uptravi | 66215-604 | Tablet, coated | New drug applications (NDA) | December 21, 2015 |
| Uptravi | 66215-602 | Tablet, coated | New drug applications (NDA) | December 21, 2015 |
| Opsumit | 66215-501 | Tablet, film coated | New drug applications (NDA) | November 4, 2013 |
| Veletri | 66215-403 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | April 22, 2010 |
| Veletri | 66215-402 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | April 22, 2010 |
| Zavesca | 66215-201 | Capsule | New drug applications (NDA) | July 31, 2003 |
| Tracleer | 66215-102 | Tablet, film coated | New drug applications (NDA) | November 20, 2001 |
| Tracleer | 66215-101 | Tablet, film coated | New drug applications (NDA) | November 20, 2001 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.